

HOW TO USE THIS INDEX

The Surgeon General's Report on Smoking and Health consists of 23 chapters and an Appendix. Each includes a detailed table of contents to lead the reader to the information sought and to give a quick overview of content.

The index reflects the contents of all 23 chapters and the Appendix. It was attempted to use the natural language of the Report whenever possible, but to achieve consistency in the terminology, some concepts had to be reworded.

Major concepts are expressed in primary terms (in bold, all upper case letters), which are modified by the secondary terms (indented, lower case, followed by page numbers), in order to convey the specific topic. In order to lead the reader to primary terms related to the one of interest, cross references follow many primary terms, e.g.

ALLERGY


*(See also ALLERGY, TOBACCO;
HYPERSENSITIVITY)*

If a certain concept could have appeared as more than one primary term, the reader is referred to the primary term actually used in the following manner:

Areca nut

See BETEL NUT

Secondary terms are followed by the pagination. The latter consists of one bold figure, referring to the Report chapter, a colon, followed by the page number(s). The following examples illustrate this:



17:6 (This entry refers to Chapter 17, page 6.)

17:9-12, 18:7, A:6-9 (This entry refers to Chapter 17, pages 9-12; Chapter 18, page 7; and Appendix, pages 6-9.)

INDEX

ABORTION

- in female tobacco workers, 8:9
- maternal smoking and, 8:9, 8:30-32
- relative risk for smokers vs. nonsmokers, 8:31-32
- research needs, 8:77
- in smokers vs. nonsmokers, 8:30-32
- smoking and wanted vs. unwanted pregnancy and, 8:30-32

ABRUPTIO PLACENTAE

- gestational age and risk in smoking vs. nonsmoking mothers, 8:44, 8:46
- maternal smoking and, 8:39
- smoking and stillbirth, 8:39
- smoking levels and, 8:39
- smoking levels and perinatal mortality, 8:40

ABSENTEEISM

- effect of smoking, 3:8, 3:10
- effect of smoking, summary of findings, 1:12-13
- smokers vs. nonsmokers vs. ex-smokers, 3:8, 3:12-14

ABSORPTION

- nicotine, 14:85
- toxic elements in respiratory tract, 14:98

ABSTINENCE

- males vs. females, 15:28
- smoking habit and, 15:26

Abstinence syndrome

- See* TOBACCO WITHDRAWAL SYNDROME

ACADEMIC ACHIEVEMENT

- smoking and, 17:16, 20:8
- Teenage Self Test scores and, 20:22

ACCIDENTS

- smoking on the job and, 7:15

ACROLEIN

- eye and nose irritation and, 11:26
- humectants and, 14:63

- levels, effect of smoking in enclosed spaces, 11:25

Adenoma

- See* NEOPLASMS

ADDICTION

- (*See also* HABITUATION)

- cessation of smoking and, 18:22
- identification of addicted smokers, 18:13
- laboratory models, 16:12
- to nicotine, 16:7-9, 18:12
- smoking vs. drug addiction, 16:10-11

ADOLESCENTS

- (*See also* TEENAGERS)

- antismoking education, 17:6, 17:17-22, 20:5-26, 21:25
- attitudes toward smoking, 17:5-6, 17:8-10
- cessation of smoking, 18:19
- drug abuse and smoking, 17:23, 18:14
- effect of school smoking policies, 23:8-12
- illegality of tobacco use, 23:7
- influence of role models, 21:11-14
- recommendations for prevention of smoking, 17:22-25
- smoking habit, 17:7-8, 18:16, 23:9
- smoking habit in males vs. females in the United States, 19:21
- social factors in smoking initiation, 17:12-17

Adrenaline

- See* CATECHOLAMINES

ADULT EDUCATION

- Adult Basic Education, 21:7, 21:9
- Adult Performance Level Program, 21:7-9
- antismoking education, 21:10-11, 21:22-26
- participation statistics, 21:5-6

ADULTS

- cigarette consumption patterns in the United States, A:23
- increase of cigarette consumption over time, A:17
- patterns of smoking prevalence, A:11, A:12-14
- self-reported smoking characteristics, A:21-22
- smoking prevalence by educational level, A:14-16
- smoking prevalence by family income, A:14-16
- smoking surveys in the United States, A:8-10, A:18

ADVERTISING

- antismoking information, 19:9, 21:15
- effect on smoking rates, 18:22-23, 21:23
- effect on youth, 17:5-6, 17:15, 17:22, 20:6-7
- Federal Communications Commission rules, A:7
- lung disease campaign, 21:10
- restrictions in Denmark, 18:22, 22:6
- revenues from tobacco interests, 21:18

ADVERTISING BAN

- effect on consumption in Great Britain, 18:22-23
- effect on consumption in Ireland, 18:22
- effect on consumption in Italy, 18:22
- effect on consumption in New Zealand, 18:22
- effect on consumption in the United States, 18:23
- effect on per capita consumption, A:8

ADVISORY COMMITTEE TO THE SURGEON GENERAL ON SMOKING AND HEALTH

- summary of 1964 Report, 1:7-9
- summary of 1979 Report, 1:10-35

AFLATOXIN B₁

- as tobacco contaminant, 14:22

AGE

- initiation of smoking and, 17:8-9
- motivation for smoking and, 18:11
- recidivism and, 19:31

AGE GROUPS

- absenteeism and, 3:13
- bed disability and, 3:12

- cessation of smoking and, 3:18
- heart conditions and, 3:19
- mortality ratio, 2:17
- mortality ratio, mortality rates and excess deaths in the United States, 2:11
- percent distribution of cigar, cigarette and pipe smokers in the United States, 13:9

AGING

(See also **TOBACCO AGING**)

- atherosclerosis in smokers vs. nonsmokers and, 4:12, 4:14
- effect on antipyrine pharmacokinetics in smokers vs. nonsmokers, 12:29-30

Agricultural chemicals

See **PESTICIDES**

AIR POLLUTION

- bronchopulmonary diseases and, 1:19
- chronic obstructive lung disease and, 6:36
- in lung neoplasm etiology, 5:25-27
- lung pathology in smokers vs. nonsmokers and, 6:36-37
- smoking and chronic obstructive lung disease and, 6:37-38
- smoking and respiratory symptoms and, 6:37

AIRPLANES

- effect of smoking on nonsmokers, 11:26

ALBANY CIVIL SERVANT STUDY

- angina pectoris, 4:46
- sudden cardiac death, 4:43

ALCOHOL

- and benzo(a)pyrene in esophageal neoplasm induction in animals, 5:44
- content of cigarette smoke, 14:42
- pharmacokinetics in smokers vs. nonsmokers, 12:39

ALCOHOL CONSUMPTION

- beer, and motivation for smoking, 18:11
- cessation of smoking and, 18:20
- effect on esophagus, 13:25
- interactive effect with smoking on atherosclerosis, 4:13, 4:15
- smoking, coffee drinking and peptic ulcer and, 9:6
- smoking and laryngeal neoplasms and, 5:32, 5:34

smoking and oral neoplasms and, 5:40-41
smoking in esophageal neoplasm etiology and, 5:43-44
smoking rate and, 16:13, 18:14

ALDEHYDES

(See also ACROLEIN)

content of cigarette smoke, 14:42
humectants and, 14:63

ALKALOID CONTENT

(See also NICOTINE CONTENT)

in cigar vs. cigarette smoke condensate, 13:11

reduction in particulate phase cigarette smoke, 14:108

ALKALOIDS, TOBACCO

(See also COTININE; NICOTINE; NORNICOTINE)

pharmacological activity, 14:93
relative molar potency in cigarette smoke, 14:96

structural formulae, 14:46

ALKANE CONTENT

in cigarette smoke, 14:45

ALKENES

in cigarette smoke, 14:48

ALLERGIC RHINITIS

passive smoking and, 10:21
smoking and, 10:20

ALLERGY

(See also ALLERGY, TOBACCO; HYPERSENSITIVITY)

childhood respiratory infections and, 10:12

clinical manifestations, 10:20

definition, 10:8-9

diagnosis, 10:5

effect of tobacco smoke exposure, 10:14

involuntary smoking and, 11:31

nicotine in induction of, 10:22

predisposition, and broncho-constriction and chest infections, 10:22

skin test reactions to tobacco leaf extracts in smokers vs. nonsmokers, 10:13

smoking and, summary of findings, 1:23-24

thromboangiitis obliterans and, 4:60
tobacco and tobacco smoke in etiology of, 10:5, 10:23-24

tobacco smoke as secondary factor, 10:8

ALLERGY, TOBACCO

asthma and, 10:21

basic mechanisms, 10:5

cardiovascular diseases and, 10:22-23

diagnosis, 10:24

diagnostic criteria, 10:6-7

epidemiology, 10:12-14

tests, 10:6

treatment and prevention, 10:24

Alveolar macrophages

See MACROPHAGES, ALVEOLAR

AMBIENT AIR QUALITY STANDARD

smoking in enclosed spaces and, 11:21

AMBLYOPIA, TOBACCO

etiology, 12:66

AMERICAN ASSOCIATION FOR HEALTH, PHYSICAL EDUCATION, AND RECREATION

recommendations for school programs, 17:15

statement on school smoking policies, 23:8-9, 23:13-14

training of health educators, 23:32

AMERICAN CANCER SOCIETY

campaign against hospital cigarette sales, 22:20

group cessation program, 19:10

study of physicians' smoking habits, 22:11

survey of teachers' smoking habits and attitudes, 17:15, 21:13

withdrawal clinics, 21:16

youth antismoking programs, 20:22

youth smoking studies, 17:8, 18:15, 21:11-12

AMERICAN DENTAL ASSOCIATION

school programs on oral health, 20:23

AMERICAN HEALTH FOUNDATION

cessation program, 21:16

"Know Your Body" program, 21:20

AMERICAN HEART ASSOCIATION

adolescent antismoking demonstration projects, 20:22

withdrawal clinics, 21:16

AMERICAN LUNG ASSOCIATION

antismoking curriculum models, 20:22-23

withdrawal clinics, 21:16

AMERICAN MEDICAL ASSOCIATION

antismoking advice to patients, 22:16

AMERICAN PHARMACEUTICAL ASSOCIATION

recommendation against cigarette sales, 22:9

AMERICAN PUBLIC HEALTH ASSOCIATION

members' smoking attitudes, 22:7, 22:15

AMERICAN SCHOOL HEALTH ASSOCIATION

state school health programs survey, 23:5-23-7

AMINES

bladder neoplasms and, 14:47
content in cigarette smoke, 14:41, 14:47
content in tobacco and tobacco smoke, 12:74

AMMONIA CONTENT

in cigar smoke, 14:39
in cigarette smoke, 14:39
in sidestream smoke, 14:41

Amount smoked

See **SMOKING LEVELS; CIGARETTE CONSUMPTION**

ANALYTICAL METHODS

fiber optic probe system, 14:9
Thermal Energy Analyzer, 14:9

ANGINA PECTORIS

(See also **CORONARY HEART DISEASE**)

clinical features and prognosis, 4:46
effect of carbon monoxide and nicotine, 4:47
effect of involuntary smoking, 11:30-31
effect of low level carbon monoxide exposure, 11:30, 11:34
effect of nicotine, 4:39
effect of smoking, 4:47
morbidity ratio, effect of smoking levels, 4:48
morbidity ratio in smokers vs. non-smokers, 4:48
research needs, 4:47, 4:49

ANIMAL MODELS

atherosclerosis, 4:9, 4:16-18
cerebrovascular disease, 4:49-50
esophageal neoplasms, 5:44
laryngeal neoplasms, 5:34-35
lung neoplasms, 29:31
myocardial infarction, 4:20, 4:40
oral neoplasms, 41-42

pancreatic neoplasms, 5:51-53
peripheral vascular disease, 4:53
sudden cardiac death, 4:43
tobacco induced carcinogenesis, 5:53-54

tobacco induced carcinogenesis, summary of methods, 5:29-30

ANNOYANCE

effect of involuntary smoking in nonsmokers, 11:25
smoking in public transportation and, 11:34

ANOXIA

maternal smoking and infant mortality, 8:47

ANTEPARTUM HEMORRHAGE

maternal smoking and, 8:39

ANTICOAGULANTS

effect of smoking on metabolism, 12:54-55

ANTIGEN-ANTIBODY REACTIONS

effect of cigarette smoke in mice, 12:59
response to viral vaccines in smokers vs. nonsmokers, 12:58-59

ANTIPYRINE

clearance in lung neoplasm patients, 12:31
pharmacokinetics in smokers vs. non-smokers, 12:29-31

ANTIGENS

identification in tobacco leaf and smoke, 10:11
tobacco proteins, 10:11

ANTISMOKING CAMPAIGNS

(See also **CESSATION OF SMOKING; PREVENTION OF SMOKING**)

absenteeism and, 3:8
in asbestos plants, 7:12
in coal miners, 7:15
education in Winnipeg schools, 20:13
education of youth in Great Britain, 20:10
effect on per capita consumption, A:7
effect on youth, 17:17-18
effectiveness, 18:23, 19:9-10
German youth, 20:8-9
hospital smoking policy guidelines in Canada, 22:20-21
hospital smoking policy guidelines in Great Britain, 22:20

- hospital smoking policy guidelines in Scotland, 22:21
- in occupational settings, 7:18-19
- Women's Christian Temperance Union, 23:12-13
- youth to youth programs, 20:9
- ANTISMOKING MATERIALS**
- posters, 19:9
- in school programs, 20:8, 20:7-15, 20:17
- ANTISOCIAL TENDENCIES**
- smoking habit and, 18:9
- ANTITOBACCO CHEWING GUM**
- in smoking reduction, 19:17
- ANTITRYPSIN DEFICIENCY**
- bronchopulmonary diseases and, 1:19
- in emphysema etiology, 6:33-34
- risk for chronic obstructive lung disease, 6:33-34
- ANXIETY**
- (See also **STRESS**;
NEUROTICISM)
- in deprived smokers, 16:7-8
- reduction by smoking, 16:11
- smoking habits in medical students and, 18:8
- AORTIC ANEURYSM**
- clinical and histopathological features, 4:55
- coronary heart disease and, 4:55
- mortality ratios, effect of smoking levels, 4:55
- research needs, 4:56
- smoking in etiology of, 4:56
- Areca chewing**
- See **BETEL CHEWING; TOBACCO CHEWING**
- Areca nut**
- See **BETEL NUT**
- AROMATIC AMINES**
- (See also **HETEROCYCLIC COMPOUNDS; NAPHTHYLAMINES**)
- bladder neoplasms and, 5:47
- occupational hazards, 7:16
- smoking and occupational risk of bladder neoplasms, 7:16
- AROMATIC HYDROCARBONS**
- (See also **BENZANTHRACENES; BENZO(a)PYRENE; METHYLCHOLANTHRENE**)
- aryl hydrocarbon hydroxylase activity
- in fetus after maternal exposure in rats, 8:66
- benzo(a)pyrene as indicator of carcinogenic potential of cigarette smoke, 14:109-110
- in cigarette smoke, 14:41-42, 14:51, 14:54
- in cigarette vs. cigar vs. pipe smoke, 13:11-12
- as cocarcinogens, 14:52
- effect of increased tobacco combustibility on reduction, 14:111
- effect on caffeine pharmacokinetics in rats, 12:32-33
- effect on cytochrome P₁-450 induction, 12:7-8
- effect on cytochrome P₁-450 synthesis, 12:16-20
- effect on drug metabolism, 12:7-9
- effect on enzyme activity, 12:7-9
- effect on enzyme activity in microsomes, 12:76
- effect on liver function, 12:7-8
- incomplete combustion and, 14:49
- maternal-fetal exchange in animals, 8:66
- reduction in particulate phase cigarette smoke, 14:109
- structural formulae, 14:53
- AROUSAL**
- effect of nicotine, 15:11
- ARSENIC CONTENT**
- in mainstream cigarette smoke, 14:59
- ARTERIES**
- effect of carbon monoxide and nicotine in animals, 4:56
- effect of smoking on atherosclerosis in distal aorta and iliac arteries, 4:53
- hyaline thickening in myocardium in smokers vs. nonsmokers, 4:16
- ARTERIOLES**
- effect of smoke inhalation in dogs, 4:18
- hyaline thickening in myocardium in smokers vs. nonsmokers, 4:16
- Arteriosclerosis**
- See **ATHEROSCLEROSIS**
- ARTIFICIAL SWEETENERS**
- bladder neoplasms and, 5:47
- ARYL HYDROCARBON HYDROXYLASE**
- (See also **ENZYMES**)
- activity, 12:7-9

- effect of benzo(a)pyrene or cigarette smoke on activity in rats, 12:29
- effect of cessation of smoking on activity, 12:41
- effect of cigarette smoke on activity in liver vs. lung, 12:76
- effect of smoking on activity, 5:57
- fetal, activity after maternal aromatic hydrocarbon exposure in rats, 8:66
- inducibility in laryngeal and lung neoplasm patients, 5:57
- role in antipyrine pharmacokinetics, 12:30-31
- role in drug metabolism, 12:7-9
- ASBESTOS**
 - occupational hazards, 7:11-13
 - smoking and laryngeal neoplasms and, 5:34
 - and smoking in lung neoplasm etiology, 5:28
- ASBESTOSIS**
 - (*See also* OCCUPATIONAL DISEASES)
 - smoking and, 7:11-13
- Ascorbic acid**
 - See* VITAMIN C
- ASPHYXIA**
 - in infants of smokers vs. nonsmokers, 8:69
- ASPIRIN**
 - consumption in smokers vs. nonsmokers, 18:13
- ASTHMA**
 - (*See also* RESPIRATORY TRACT DISEASES)
 - effect of smoking in patients, 10:22
 - passive smoking and, 10:21
 - tobacco allergy and, 10:21
 - in tobacco workers, 10:21
- ATHEROSCLEROSIS**
 - alcohol consumption and smoking and, 4:15
 - carbon monoxide and, 4:18
 - in cardiovascular disease etiology, 4:8
 - in coronary heart disease etiology, 4:7
 - effect of alcohol consumption and smoking levels, 4:13
 - effect of carbon monoxide in cholesterol fed animals, 4:17
 - effect of smoking levels, 4:8-16
 - experimental induction in animals, 4:9, 4:16-18
 - histology and pathogenesis, 4:7-10
 - in myocardial infarct etiology, 4:19-20
 - nicotine and, 14:79
 - research needs, 4:18
 - risk factors, 4:8-9
 - smokers vs. nonsmokers, 4:10-16
 - somatic cell mutation theory of pathogenesis, 4:10
 - thromboangiitis obliterans and, 4:60
- ATHLETIC PERFORMANCE**
 - smoking and, 20:8
- ATTITUDES**
 - (*See also* BEHAVIOR)
 - cessation of smoking and, 18:22
 - drug abuse, 18:10
 - parents, 17:13-14
 - teachers, 20:23, 21:12-13
 - youth, 17:5-6, 17:8, 17:10, 17:17, 17:23, 20:6, 20:13-14, 20:17-18, 20:21, 20:23, 21:11-12
- AVERSIVE THERAPY**
 - in cessation of smoking, 16:15-16
 - covert sensitization, 19:23
 - electric shock, 19:23
 - medical risks, 19:25-26
 - in multicomponent treatments, 19:19, 19:27, 19:30
 - rapid smoking, 19:24-26
 - satiation, 19:25-26
 - Schick Smoking Control Centers, 21:16
- Aza-arenes**
 - See* HETEROCYCLIC COMPOUNDS
- BEHAVIOR**
 - (*See also* ATTITUDES; MOTIVATION; PERSONALITY)
 - effect of maternal smoking on children, 1:21
 - effect on pharmacokinetics, 12:40-41
 - smoking habit and, summary of findings, 1:32-33
- BEHAVIOR, ANIMAL**
 - effect of nicotine, 15:16
 - effect of nicotine in monkeys, 15:12
 - effect of nicotine in rats, 15:11, 15:18

BEHAVIOR MODIFICATION

(See also **AVERSIVE THERAPY; STIMULUS CONTROL TREATMENT; CONTINGENCY CONTRACTING; MULTICOMPONENT TREATMENT**)

in cessation of smoking, 16:15-18, 19:19-29

BENZANTHRACENES

(See also **AROMATIC HYDROCARBONS**)

in oral neoplasm induction in hamsters, 5:42

BENZENE

threshold limit values, 14:51
tobacco pyrolysis and, 14:49

BENZO(a)PYRENE

(See also **AROMATIC HYDROCARBONS**)

as aromatic hydrocarbon indicator in cigarette smoke, 14:109-110

effect on caffeine pharmacokinetics in rats, 12:32-33

effect on fetus, research needs, 8:81

effect on maternal and fetal aryl hydrocarbon hydroxylase activity in rats, 8:66

effect on phenacetin pharmacokinetics in rats, 12:59

effect on warfarin pharmacokinetics in rats, 12:38

and ethanol in esophageal neoplasm induction in animals, 5:44

in laryngeal neoplasm induction in hamsters, 5:34-35

in lung neoplasm induction in hamsters, 5:30

maternal-fetal exchange in animals, 8:66

neoplasms in progeny after maternal exposure in mice, 8:67

in oral neoplasm induction in hamsters, 5:42

reduction methods, 14:114

structural formula, 14:53

BENZO(a)PYRENE CONTENT

in cigar vs. cigarette vs. pipe smoke, 13:11-12

in cigarette smoke condensate, 14:112

effect of smoking in enclosed spaces, 11:24

BERKELEY CHILD HEALTH AND DEVELOPMENT STUDIES, 8:14

Berkeley Project

See **SCHOOL HEALTH CURRICULUM PROJECT**

BETA-ADRENERGIC BLOCKING AGENTS

interactive effect with cigarette

smoke on airways, 12:54

interactive effect with cigarette

smoke on cardiovascular system, 12:53-54

BETA-NAPHTHYLAMINE

occupational hazards, 7:16

BETEL CHEWING

(See also **TOBACCO CHEWING**)

leukoplakia and, 5:41

in oral neoplasm etiology, 13:40-41

BETEL NUT

use in chewing tobacco, 13:39

BICARBONATE LEVELS

in infants of smokers vs. nonsmokers, 8:69

BILIRUBIN LEVELS

effect of maternal smoking on neonate, 12:34

smokers vs. nonsmokers, 12:34

BIOASSAY

ciliotoxic agents and, 14:105

in determining biological effects of tobacco leaf characteristics, 14:23, 14:25

in determining physiological response to cigarette smoke, 14:73

relationship of tobacco leaf characteristics, smoke constituents and biological response, 14:22-23

BIRTH WEIGHT

(See also **FETAL GROWTH**)

effect of carbon monoxide exposure in pregnant rats, 8:60, 14:79

effect of impaired protein metabolism in smoking mothers, 12:65-66

effect of maternal injection of nicotine in animals, 8:53

effect of maternal smoking, 8:9, 8:11-13, 8:17, 8:20-21

effect of maternal smoking, research needs, 8:78

effect of maternal smoking, summary of findings, 1:21

effect of maternal smoking and biologic and socioeconomic factors, 8:14-15
effect of maternal smoking and gestational age, 8:19-20
effect of maternal smoking and weight gain, 8:25
effect of tobacco smoke in animals, 8:52
infant mortality in smokers vs. nonsmokers and, 8:29
infants of future smokers, smokers, nonsmokers, and ex-smokers, 8:26-27

BLADDER NEOPLASMS

amines and, 14:47
artificial sweeteners and, 5:47
correlation with pancreatic neoplasms, 5:47
male vs. female smokers, 5:45-47
mortality ratio in smokers, 5:45-46
risk in ex-smokers, 5:46
smoking and occupational exposure and, 5:47
smoking and occupational exposure to aromatic amines and, 7:16
smoking and radiation and, 12:90
smoking and, summary of findings, 1:17
smoking in coal gas workers and, 7:16
smoking in etiology of, 5:45-47

BLOOD CHEMICAL ANALYSIS

albumin, creatinine and uric acid levels in smokers vs. nonsmokers, 12:40, 12:84
effect of cessation of smoking, 12:87
effect of smoking, summary of findings, 1:26

BLOOD CHOLESTEROL LEVELS

in atherosclerosis induction in animals, 4:9
in cigarette vs. cigar vs. pipe smokers, 4:61, 13:34
coronary heart disease and, 4:61-62
effect of carbon monoxide in animals, 4:17, 61
effect of smoking levels, 4:62
smokers vs. nonsmokers, 4:61-62
in smokers vs. nonsmokers vs. ex-smokers, 12:83-84

BLOOD CIRCULATION

(See also **HEMODYNAMICS**)

effect of smoking, 4:54
in maintenance of smoking habit, 15:19-20
smokers vs. nonsmokers, 15:12-13

BLOOD COAGULATION

effect of tobacco proteins, 4:60
smokers vs. nonsmokers, 12:84-85
smoking and thrombosis and, 4:59

BLOOD GLUCOSE

levels in smokers vs. nonsmokers, 12:84

BLOOD LIPIDS

effect of tobacco smoke and constituents on levels in animals, 4:61
levels in smokers vs. nonsmokers, 12:65
levels in smokers vs. nonsmokers vs. ex-smokers, 12:83-84

BLOOD PLATELETS

effect of smoking, 12:84-85

BLOOD PRESSURE

(See also **HYPERTENSION**)

effect of cigar smoking, 13:34
effect of cigarette smoke vs. nicotine, 14:87
effect of involuntary smoking in children, 11:27
effect of nicotine, 4:58, 14:79
effect of nicotine and oxprenolol, 12:54
effect of nicotine and propranolol, 12:53
effect of nicotine vs. cotinine, 14:91
effect of pipe smoking, 13:34
effect of propranolol in smokers, 12:37
effect of smoke inhalation in cats, 14:77
effect of smoking, 12:15-16
effect of smoking in enclosed spaces, 11:27
ex-smokers, 4:57
smokers vs. nonsmokers, 4:57

BLOOD PROTEINS

levels in smokers vs. nonsmokers, 12:84

BODY HEIGHT

- children, effect of maternal smoking, 8:21-23
infants, effect of maternal smoking, 8:19-21

BODY WEIGHT

(See also **OBESITY**)

- blood pressure in smokers vs. ex-smokers and, 4:57
- children, effect of maternal smoking, 8:21-23
- effect of cessation of smoking, 15:21
- effect of smoking during pregnancy, 8:24
- effect of tobacco smoke in pregnant animals, 8:53

BORON TRIFLUORIDE

- smoking and occupational exposure, 7:7

BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM

- clinical drug effects in smokers vs. nonsmokers, 12:35-37

BRAIN

- effect of nicotine, 15:8

BREAST FEEDING

(See also **LACTATION**)

- maternal smoking and, 8:51
- maternal smoking and, research needs, 8:78-79
- in smokers vs. nonsmokers, 8:48
- tobacco factory workers and, 8:48

BREATH

- carbon monoxide content as measure of tobacco usage, 15:30

BRITISH PERINATAL MORTALITY STUDY 8-29, 8:42**Bronchial clearance**

See **TRACHEOBRONCHIAL CLEARANCE**

BRONCHIAL NEOPLASMS

(See also **LUNG NEOPLASMS**)

- pipe smoking in etiology of, 13:28-29

BRONCHITIS

(See also **BRONCHOPULMONARY DISEASES; CHRONIC OBSTRUCTIVE LUNG DISEASE; OBSTRUCTIVE AIRWAY DISEASES**)

- in coal miners, 13:35
- effect of smoking on mortality, 2:41
- mortality in cigar vs. cigarette vs. pipe smokers, 13:34-35
- prevalence in the United States, 6:19
- small airways function and, 6:18
- in smokers vs. nonsmokers, 6:39
- smoking and, summary of findings, 1:18
- smoking in etiology of, 3:5

- smoking in gold miners and, 7:15

BRONCHOPULMONARY DISEASES

(See also **BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; OBSTRUCTIVE AIRWAY DISEASES**)

- air pollution and occupational exposure and, 1:19
- antitrypsin deficiency and, 1:19
- cigar and pipe smoking and, summary of findings, 1:28
- heredity and, 1:19
- smoking and, summary of findings, 1:18-19

BUSES

- effect of involuntary smoking on nonsmokers, 11:26

BUSINESSMEN

- cessation of smoking, 22:19

BYSSINOSIS

(See also **OCCUPATIONAL DISEASES**)

- smoking in cotton workers and, 7:9

CADMIUM

(See also **METALS**)

- content in mainstream cigarette smoke, 14:60
- levels in smokers vs. nonsmokers, 12:73
- occupational hazards, 7:15

CAFFEINE

- consumption and cessation of smoking, 18:20
- consumption and smoking as factors in heart disease, 18:14
- consumption in smokers vs. nonsmokers, 18:13, 18:15
- effect of aromatic hydrocarbons on pharmacokinetics in rats, 12:32-33
- effect of benzo(a)pyrene on clearance in rats, 12:32-33

CALCIUM

(See also **METALS**)

- blood levels in smokers vs. nonsmokers, 12:84

CANADIAN HOSPITAL ASSOCIATION

- hospital smoking policy recommendations, 22:20

CANADIAN PUBLIC HEALTH ASSOCIATION

members' smoking attitudes, 22:7, 22:15

Cancer

See **NEOPLASMS**

CANNABIS

(*See also* **DRUG ABUSE; MARIJUANA**)

effect on enzyme activity in animals and man, 12:42-43

CARBARYL

smoking and occupational exposure, 7:7

CARBOHYDRATES

effect of smoking on metabolism, 12:65

CARBON DIOXIDE

assimilation, and tobacco leaf quality, 14:15

cardiovascular diseases and, 4:62

CARBON DISULFIDE

cardiovascular diseases and, 4:62

CARBON MONOXIDE

absorption, 14:98

animal model for hyperkinesis, 8:65

in aortic aneurysm etiology, 4:56

atherosclerosis and, 4:18

calculation of buildup in enclosed spaces, 11:22

effect of low level exposure on angina pectoris patients, 11:30, 11:34

effect of low level exposure on chronic obstructive lung disease patients, 11:31

effect of low level exposure on coronary patients, 11:30

effect of maternal exposure on fetal growth in rats, 8:60

effect on arteries in animals, 4:56

effect on blood cholesterol levels in animals, 4:17, 4:61

effect on carboxyhemoglobin levels in dogs and monkeys, 14:80

effect on cardiovascular system in guinea pigs, 14:79

effect on cardiovascular system in monkeys, 14:80

effect on cerebrovascular circulation, 4:50

effect on exercise induced angina pectoris, 4:47

effect on fertility and pregnancy outcome in rats, 8:60

effect on fetal growth in animals, 8:52

effect on fetus, research needs, 8:80

effect on heart in monkeys with myocardial infarction, 4:40

effect on hemoglobin levels and red cell mass, 12:82-83

effect on intermittent claudication, 4:54

effect on ischemia, 4:39

effect on lung function and cardiovascular system, 11:27-8

effect on maternal and fetal carboxyhemoglobin levels, 8:71-72

effect on maternal and fetal oxygen tension, 8:61, 8:72

effect on maternal and fetal oxyhemoglobin saturation curves, 8:62, 8:72

effect on mother and fetus after maternal exposure in monkeys, 8:65

effect on newborn animals, 8:65

effect on pregnant mother and fetus in animals, 8:57

effect on psychomotor performance, 11:28, 11:34

effect on tissue oxygenation, 8:61

effect on smoking habit, 15:6

hypoxia of sheep fetus and, 8:63-65 in maintenance of smoking habit, 15:15

maternal-fetal exchange in sheep, 8:59

maternal-fetal exchange in sheep and dogs, 8:58

metabolism in maintenance of smoking habit, 15:17

monitoring in cessation studies, 19:7, 19:20

myocardial infarct and, 4:20

occupational hazards, 7:8

reduction methods, 14:114

smoke dosimetry and, 14:75

smoking and ambient air quality standard, 11:21

in sudden cardiac death induction in cholesterol-fed monkeys, 4:45

CARBON MONOXIDE LEVELS

(See also **CARBOXYHEMOGLOBIN LEVELS**)

- in breath, and carboxyhemoglobin levels in blood, 15:30
- in cigar smoke, 14:38
- in cigar vs. cigarette smoke, 12:12
- in cigar vs. pipe smoke, 14:104
- in cigarette smoke, 14:38
- effect of filters, 14:105
- effect of smoking in airplanes and buses, 11:26
- effect of smoking in enclosed spaces, 11:15, 11:33-34
- in main- and sidestream smoke, 11:15
- reduction in cigarette smoke, 14:104
- in tobacco smoke, and health characteristics, 3:11
- in various tobacco products, 11:15

CARBOXYHEMOGLOBIN LEVELS

(See also **CARBON MONOXIDE LEVELS**)

- angina pectoris, intermittent claudication and myocardial infarction and, 4:54
- carbon monoxide occupational exposure in smokers vs. nonsmokers and, 7:8
- cigarette smoke inhalation and, 2:21
- in determination of inhalation levels in cigar and pipe smokers, 13:18
- effect of carbon monoxide in dogs and monkeys, 14:80
- effect of involuntary smoking, 11:21, 11:23
- effect on driving ability, 11:28-29
- effect on fetal blood flow, 8:72-73
- effect on fetal mortality in sheep, 8:62-63
- effect on maternal and fetal oxygen tension, 8:61-64, 8:72-73
- as indicator of carbon monoxide in blood, 3:12
- in infants of smokers vs. nonsmokers, 8:69
- maternal, effect of smoke inhalation in pregnant sheep, 8:53
- maternal, effect on placental oxygen consumption, 8:68-69
- maternal and fetal, effect of carbon monoxide, 8:70-72
- maternal and fetal, effect of maternal smoking, 8:70

- maternal and fetal, in monkeys, 8:65
- maternal and fetal, in nonsmokers, 8:70
- maternal and fetal, in rabbits, 8:60
- maternal and fetal, in sheep, 8:58-59, 8:61
- maternal and fetal, oxyhemoglobin saturation curves and, 8:62-63
- in measuring tobacco usage, 15:29
- in methylene chloride workers, 7:8-9
- monitoring in smoking cessation, 19:7
- in nonsmokers, 11:23
- in nonsmoking blood donors, 11:23
- as smoke inhalation indicator, 14:75

CARBOXYLIC ACIDS

- levels in tobacco varieties, 14:57

CARCINOEMBRYONIC ANTIGEN

- in colonic neoplasm diagnosis, 12:59-62
- levels in smokers vs. nonsmokers, 12:61-62
- levels in smokers vs. nonsmokers vs. ex-smokers, 12:86
- in lung neoplasm diagnosis, 12:61

CARCINOGENESIS

(See also **NEOPLASMS**)

- catechols and, 14:106
- cigarette tar and beta radiation in mice, 7:10
- effect of polyaromatic hydrocarbon reduction, 14:109
- interaction of carcinogens, cocarcinogens and tumor promoters, 5:54-55
- isoprenoids in, 14:49
- mechanisms, 5:53-58
- multi-stage model, 5:58
- polynuclear aromatic hydrocarbons in, 14:51-52
- role of enzyme activity, 5:55, 57
- tobacco in animals, 5:53-54
- tobacco in animals, summary of methods, 5:54-55
- tobacco tars in animals, 13:31-32

CARCINOGENS

(See also **COCARCINOGENS; TUMOR PROMOTERS**)

- cigar and pipe tobacco condensates, 1:28
- in cigar vs. cigarette vs. pipe tars, 13:30-32
- cigarette smoke constituents, 1:30
- metals in tobacco, 14:59-60

- in tobacco smoke gas phase, 5:54-55
 - tobacco smoke PAH structural formulae, 14:53
 - in tobacco smoke particulate phase, 5:54-56, 14:65
- CARDIOVASCULAR CURRICULUM EDUCATION PROJECT**
programmed instruction, 23:19, 23:21-22
- CARDIOVASCULAR DISEASES**
(See also **CORONARY HEART DISEASE; CEREBROVASCULAR DISEASES; ISCHEMIA; MYOCARDIAL INFARCT**)
- atherosclerosis in etiology of, 4:8
 - cessation of smoking as preventive medicine, 4:66
 - cessation of smoking in patients, 22:18, 22:17
 - cigar and pipe smoking and, summary of findings, 1:28
 - cigar smoking in etiology of, 13:32-34
 - effect of involuntary smoking, 11:29-30
 - effect of oral contraceptives and smoking on risk, 4:60-61
 - effect of smoking on mortality ratio, 2:39
 - mortality in cigar vs. cigarette vs. pipe smokers, 13:33-34
 - mortality ratio in smokers vs. non-smokers in Japan, 4:21, 4:34-35
 - nicotine and, 14:79
 - pipe smoking in etiology of, 13:32-34
 - research needs, 4:64-66
 - smoking and, summary of findings, 1:13-15
 - smoking and carbon monoxide occupational exposure and, 7:8
 - sudden cardiac death, 4:42-43
 - tobacco smoke constituents and, 4:62-63
- CARDIOVASCULAR SYSTEM**
(See also **ARTERIES; ARTERIOLES; HEART**)
- allergic response to tobacco, 10:22-23
 - effect of carbon monoxide exposure, 11:27-28
 - effect of carbon monoxide in guinea pigs, 14:79
 - effect of carbon monoxide in monkeys, 14:80
 - effect of cessation of smoking, 15:20-21, 15:23
 - effect of nicotine, 12:52-54, 14:89
 - effect of nicotine in animals with coronary heart disease, 4:40
 - effect of nicotine or tobacco smoke in animals with myocardial infarct, 4:45
 - effect of propranolol and nicotine, 12:53
 - effect of propranolol in smokers, 12:37
 - effect of rapid smoking, 19:25-26
 - effect of smoke inhalation, 14:74-75
 - effect of smoking, 15:12-13, 15:19
 - maternal and fetal, effect of nicotine injection in animals, 8:55-56
- CASING MATERIALS**
effect on smoke constituents, 14-28
- CATECHOLAMINES**
effect of nicotine in rats, 14:88
effect of nicotine on levels, 14:78, 14:89
effect of smoking on plasma levels, 14:88
fatty acids and, 14:90
hyperglycemia and, 14:90
smoking habit and, 15:8
- CATECHOLS**
in mainstream cigarette smoke, 14:54
reduction in gas phase cigarette smoke, 14:106
in sidestream cigarette smoke, 14:54
structural formulae, 14:56
- CENTRAL NERVOUS SYSTEM**
effect of carbon monoxide and nicotine on blood circulation, 4:50
effect of cessation of smoking, 15:21
effect of cigarette smoke, 15:11
effect of nicotine, 14:89
effect of smoking, 15:18-19
fetal and neonatal, effect of maternal nicotine injection in animals, 8:56-57
- CEREBROVASCULAR DISEASES**
(See also **CARDIOVASCULAR DISEASES**)
animal models, 4:49-50
cigar smoking in etiology of, 13:32-33
clinical diagnostic classification, 4:49

effect of smoking on risk, 4:50-52
mortality rates and ratios in male
vs. female smokers vs. nonsmokers,
4:51
pipe smoking in etiology of, 13:32-33
research needs, 4:52
risk factors, 4:49
smoking and, summary of findings,
1:14-15
smoking in etiology of, 4:50

CESSATION OF SMOKING

(*See also* **ANTISMOKING CAMPAIGNS; PREVENTION OF SMOKING; WITHDRAWAL CLINICS**)

adult programs, 21:14-15, 21:22-26
age groups and sex ratio and, 3:18
antismoking campaigns and, 19:9-10
behavioral interventions, 16:14-18,
19:19-29
businessmen, 22:19
cardiovascular diseases and, summary
of findings, 1:14-15
college students, 22:18
coronary heart disease prevention
programs, 19:14-16, 19:34, 21:24-
25
counseling, 19:12-14
degree of deprivation and, 15:27
drug therapy, 19:16-17
early behavioral effects, 15:22
early physiological effects, 15:20-22
effect on bladder neoplasm risk, 5:45
effect on blood chemical analysis,
12:87
effect on blood circulation, 4:54
effect on calcium and iodine levels
in blood, 12:84
effect on carcinoembryonic antigen
levels, 12:86
effect on coronary heart disease
morbidity and mortality ratios,
4:28-31, 4:34-35, 4:38
effect on enzyme activity, 12:41
effect on laryngeal neoplasm risk,
5:34, 5:37-38
effect on lung function, 6:22-23
effect on lung neoplasm risk and
mortality ratio, 5:24-26
effect on morbidity, summary of
findings, 1:12-13

effect on mortality, 2:26-30
effect on mortality ratio, summary
of findings, 1:11
evaluation of programs, 1:32-33
hypnosis, 19:17-18
laryngeal neoplasms and, summary
of findings, 1:16-17
long term physiological effects,
15:22-24
lung neoplasms and, summary of
findings, 1:16
medical students, 22:18
methods, 19:16-30
motivation, 18:19-20
myocardial infarct patients, 19:14
nicotine pharmacology and, 14:94,
14:97
obesity and, 12:67
patients with respiratory or cardio-
vascular diseases, 22:18
personality and, 18:17-18, 18:21-22
personality of smokers vs. nonsmokers,
vs. ex-smokers and, 15:24
physician's advice and, 3:15-18, 21:11
pregnant women, 22:16, 22:18, 22:23
as preventive medicine for cardiovas-
cular diseases, 4:66
program in Sweden, 19:15
recidivism, 15:22-23
research design, 16:17, 19:5-9, 19:32-
36
self-motivated, 19:33, 19:35, 21:15
smoker's reporting and, 15:31
Smoking Withdrawal Study Center
(Toronto), 19:11
tobacco withdrawal syndrome time
course, 15:26
and weight gain, 19:31
withdrawal clinics in Great Britain,
19:15

Chewing gum

See **NICOTINE CHEWING GUM; ANTITOBACCO CHEWING GUM**

CHILDREN

(*See also* **INFANTS**)

attitudes toward smoking, 17:5-6
effect of involuntary smoking on al-
lergies, 10:14
effect of involuntary smoking on
heart rate and blood pressure,
11:27
effect of maternal smoking during

pregnancy, 8:21-23
effect of parental smoking, 11:31
effect of parental smoking on respiratory disease prevalence, 11:32, 11:34
Health Activities Project, 21:20
smoking and respiratory tract diseases, 6:11

CHLORINE

occupational hazards, 7:10

CHLOROMETHYL ETHERS

occupational hazards, 7:15-16
and smoking in lung neoplasm etiology, 5:29

Cholesterol

See **BLOOD CHOLESTEROL LEVELS**

CHRONIC OBSTRUCTIVE LUNG DISEASE

(*See also* **BRONCHITIS; BRONCHOPULMONARY DISEASES; EMPHYSEMA; OBSTRUCTIVE AIRWAY DISEASES; RESPIRATORY TRACT DISEASES**)

air pollution and, 6:36
cigar smoking in etiology of, 13:34-38
effect of low level carbon monoxide exposure, 11:31
effect of smoking on mortality, 2:41
mortality, 6:10
mortality in cigar vs. cigarette vs. pipe smokers, 13:34-35
nitrogen oxide absorption and, 14:99
pipe smoking in etiology of, 13:34-38
small airways function and, 6:11-12
small airways function and respiratory symptoms and, 6:13, 6:18
smoking and air pollution and, 6:37
smoking and antitrypsin deficiency and, 6:34
smoking and heredity and, 6:35-36
smoking and occupational exposure to dust and, 6:36
smoking and socioeconomic status and, 6:38

smoking as risk factor, research recommendations, 6:41-42

smoking history and, 6:10

Chronic obstructive pulmonary disease

See **CHRONIC OBSTRUCTIVE LUNG DISEASE**

Cigar smoke

See **SMOKE, CIGAR**

CIGARETTE CONSUMPTION

(*See also* **SMOKING LEVELS**)

annual per capita, United States 1925-1950, A:5
annual per capita, United States 1950-1978, A:5
annual per capita, United States 1963-1977, A:7
changes from 1963-1977, A:6
effect of composition, A:18-19
FTC, DOA, and Maxwell Report statistics, A:6
historical trends in the United States, 1:5
increase in adults over time, A:17
low-tar brands, A:20-21
reasons for increase, A:17
in the United States, A:22-23, 14:13

CIGARETTE MANUFACTURING

effect on carcinogenicity, 14:29-30
effect on cigarette smoke constituents, 14:28-30
levels in the United States, 14:11
role in smoke constituent delivery, 14:9
tobacco types in the United States and, 14:13

CIGARETTE PAPER

effect on carbon monoxide levels, 14:104
effect on smoke constituents, 14:29
effect on temperature profile, 14:35

Cigarette smoke

See **SMOKE, CIGARETTE**

Cigarette smoke, gas phase

See **GAS PHASE, CIGARETTE SMOKE**

Cigarette smoke, particulate phase

See PARTICULATE PHASE, CIGARETTE SMOKE; TARS, CIGARETTE

Cigarette smoking

See SMOKING

Cigarette tars

See TARS, CIGARETTE

CIGARETTES

(*See also* SMOKE, CIGARETTE; SMOKERS; SMOKING, CIGARETTE; TOBACCO, CIGARETTE)

effect of design on ciliotoxicity,

14:105

effect of nicotine and tar content on mortality, 2:22

effect of static burning temperature on smoke formation, 14:36

experimental, carcinogenicity, 14:29-30

manufacturing levels, 14:11

nicotine reduction, 14:44

phenol levels in filtered vs. nonfiltered, 14:57

pyrolysis reactions, 14:9

sales weighted average tar content 1954-1977, A:19

tar reduction, 14:43

temperature profiles, 14:35-36

United States Government definition, 13:10

CIGARETTES, FILTER

consumption patterns, A:23

increase in consumption, A:19

CIGARETTES, HIGH-NICOTINE

anxiety levels and, 16:7-8

effect on self-regulation of smoking, 16:19

CIGARETTES, LESS HAZARDOUS

effect on coronary heart disease mortality rates, 4:38

effect on laryngeal neoplasm risk, 5:34-36

effect on lung neoplasm mortality ratio, 5:15-17

effect on lung neoplasm risk, 5:16, 5:18-19

effect on mortality ratio, 1:11

effect on mortality ratio in males vs. females, 2:23-25

isoprenoids and, 14:49

nicotine reduction and, 14:108

research and development, 1:31

research recommendations, 14:120

tar reduction and, 14:108

CIGARETTES, LOW-NICOTINE

anxiety levels and, 16:7-8

consumption trends, 16:16-17, 19:29

degree of deprivation and, 15:27

dependence and, 14:98

effect on mortality ratio, 2:23

effect on self-regulation of smoking, 16:19

promotion in hospital setting, 22:22

smoker preference, 15:8

CIGARETTES, LOW-TAR

(*See also* CIGARETTES, LESS HAZARDOUS)

consumption patterns, A:20-21

market share 1967-1978, A:20-21

trends in tar and nicotine content, A:23-24

CIGARETTES, NON-NICOTINE

as reinforcers, 16:8-9

CIGARETTES, NONTOBACCO

effect on ciliary activity in protozoans, 6:32

patellar reflexes and, 14:92

CIGARS

(*See also* SMOKE, CIGAR; SMOKERS, CIGAR; SMOKING, CIGAR; TOBACCO, CIGAR)

consumption in the United States, 14:13

effect of manufacturing process, 14:30

smoking characteristics of ex-cigarette smokers, 19:29

tar levels, 14:44

United States Government definition 13:10

CIGARS, LITTLE

effect of filters on nitrogen oxide content, 14:39

nicotine levels, 14:44, 14:87

tar levels, 14:44

CILIARY ACTIVITY

(*See also* MUCOCILIARY SYSTEM)

effect of cigarette smoke, 6:32

effect of phenol, 14:81

- effect of smoke from nontobacco cigarettes in protozoans, 6:33
effect of smoking, 10:14-15
effect of tobacco smoke, 6:32
gas phase cigarette smoke and, 14:105
- CILIATOXICITY**
agent reduction methods, 14:114
cigar smoke, 13:36-37
cigarette design and, 14:105
effect of carbon filters, 14:107
effect of charcoal filtration, 14:105
gas phase, cigarette smoke, 14:106
gas phase, tobacco smoke, 5:54-55
reduction in gas phase, cigarette smoke, 14:104-105
- COAL**
dust, occupational hazards, 7:9
- COCARCINOGENS**
(*See also* **CARCINOGENS; TUMOR PROMOTERS**)
asbestos and cigarette smoke, 5:28
catechols and cigarette smoke, 14:106
polynuclear aromatic hydrocarbons, 14:52
role in carcinogenesis, 5:54
in tobacco smoke particulate phase, 5:54-55
uranium and cigarette smoke, 5:28
- Coffee**
See **CAFFEINE**
- COLLABORATIVE PERINATAL PROJECT OF THE NINCDS**, 8:30, 8:45
- COLONIC NEOPLASMS**
carcinoembryonic antigen test in diagnosis of, 12:59-62
- COMMUNITY PROGRAMS**
antismoking education, 23:14-15
D-day project (Monticello, Minnesota), 21:25
- CONGENITAL MALFORMATIONS**
effect of carbon monoxide exposure in pregnant rats, 8:60-61
effect of maternal nicotine injection in mice, 8:54
- CONTINGENCY CONTRACTING**
aversive therapy and, 19:30
modification of smoking behavior, 19:21-22, 19:28-29
stimulus control treatment and, 16:16
- CONTRACEPTIVES, ORAL**
cardiovascular diseases and smoking and, summary of findings, 1:14
effect on high density lipoprotein levels, 4:62
interactive effect with smoking on cardiovascular disease risk, 4:50, 4:60-61
interactive effect with smoking on myocardial infarct risk, 4:35
interactive effect with smoking on subarachnoid hemorrhage risk, 4:60-61
mortality risk compared with pregnancy and childbirth, 12:52
myocardial infarct and smoking and, 12:51-52
stroke and smoking and, 12:51
thromboembolism and smoking and, 4:59, 12:51
- COOPERATIVE EXTENSION SERVICE**
dissemination of health information, 21:22
- CORONARY HEART DISEASE**
(*See also* **ANGINA PECTORIS; ATHEROSCLEROSIS; ISCHEMIA; MYOCARDIAL INFARCT; SUDDEN CARDIAC DEATH; THROMBOSIS**)
aortic aneurysm and, 4:55
atherosclerosis in etiology of, 4:7
cigar smoking in etiology of, 13:32-33
effect of age, smoking duration and smoking levels on annual probability of death, 4:35
effect of low level carbon monoxide exposure, 11:30
effect of physical activity in smokers, 4:38
heredity and, 4:66
high density lipoprotein levels and, 4:61-62
morbidity and mortality rates and ratios in ex-smokers, 4:28-31, 4:34-35, 4:38
morbidity and mortality ratios in smokers vs. nonsmokers, 4:22-23, 4:36-37
mortality ratio in smokers, 2:39
nicotine and, 14:89
pipe smoking in etiology of, 13:32-33

risk factors, 4:21, 4:36
smoking and, 4:21
smoking and hypertension and, 4:58
sudden cardiac death and, 4:41-43

CORONARY PREVENTION PROGRAMS
effect on cessation of smoking,
19:14-16, 19:34, 21:24-25
North Karelia Project, 19:15
workplace detection program, 22:16-17, 22:19

Cost
See **ECONOMICS**

COTININE
(*See also* **ALKALOIDS, TOBACCO; NICOTINE METABOLITES**)
in amniotic fluid after maternal injection in animals, 8:54
effect on blood pressure and heart rate, 14:91
levels in measuring tobacco usage, 15:30
metabolism, 14:94
relative molar potency in cigarette smoke, 14:96
as smoke inhalation indicator, 14:75
structural formula, 14:46

COTTON
dust, occupational hazards, 7:9

COUGH
effect of chloromethyl ether exposure in smokers vs. nonsmokers, 7:16

Curing
See **TOBACCO CURING**

CYANIDES
(*See also* **HYDROGEN CYANIDE; THIOCYANATE LEVELS**)
absorption, 14:99
in cigarette smoke, 14:39-40
effect on hemoglobin levels and red cell mass, 12:83

Cyclopentanediones
See **HETEROCYCLIC COMPOUNDS**

CYTOCHROME 65
role in drug metabolism, 12:11, 12:13

CYTOCHROME P-450
role in drug metabolism, 12:7-8, 12:10-20
spectral properties, 12:18-20
storage and activity sites, 12:16

CYTOCHROME P₁-450
effect of aromatic hydrocarbons, 12:7-8
effect of aromatic hydrocarbons on synthesis, 12:17-20
spectral properties, 12:18-20

D-DAY PROJECT (MONTICELLO, MINNESOTA)
community cessation program, 21:25

DDT
in breast milk of smoking mothers, 8:51
as tobacco residue, 14:61

DENTISTS
antismoking advice to patients, 21:11-12, 22:16-17
smoking habits, 22:12-14

DEPENDENCE
effect of smoking characteristics, 14:97, 15:25
low-nicotine cigarettes and, 14:98
in maintenance of smoking habit, 15:17-18
nicotine and, 14:97
tobacco withdrawal syndrome and, 15:24-25

DEPRIVATION
effect of gradual reduction, 15:27
low-nicotine cigarettes and, 15:27

DERMATITIS, CONTACT
in tobacco workers, 10:23

DEXAMETHASONE
effect of smoking on corticosteroid secretion, 12:37

DIABETES
peripheral vascular disease in smokers vs. nonsmokers and, 4:53

DIBENZ(a, h)ANTHRACENE
structural formula, 14:53

DIENES
in cigarette smoke, 14:41

DIET
in atherosclerosis induction in animals, 4:9
pancreatic neoplasms and, 5:51

DIETHYLNITROSAMINE
(*See also* **NITROSAMINE CONTENT; NITROSAMINES**)
effect of smoking on levels in enclosed spaces, 11:25
in lung neoplasm induction in hamsters, 5:30

DINITRO-ORTHO-CREOSOL
smoking and occupational exposure,
7:7

DIURNAL VARIATIONS
in smoking habit, 15:25-26

DOSIMETRY
effect of carbon monoxide levels,
14:75
in smoke inhalation methodology,
14:74

DRIVING ABILITY
effect of alcohol and carbon monoxide,
11:29
effect of carboxyhemoglobin levels,
11:28

DRUG ABUSE
(See also **CANNABIS; MARIJUANA**)
attitudes and smoking habit, 18:10
smokers vs. nonsmokers, 18:13-15
smoking in youth and, 17:23

DRUG METABOLISM
(See also **PHARMACODYNAMICS; PHARMACOKINETICS**)
effect of aromatic hydrocarbons,
12:7-9
effect of smoking, summary of findings,
1:25-26
ethanol, in smokers vs. nonsmokers,
12:39
mechanisms of enzyme induction,
12:20-22
role of aryl hydrocarbon hydroxylase,
12:7-9
role of cytochrome b₅, 12:11, 12:13
role of cytochrome P-450, 12:7-8,
12:10-20
role of microsomal electron transport
system, 12:10-15
role of microsomal mixed function
oxidase systems, 12:10-22
role of NADPH reductase, 12:10-15
warfarin, effect of smoking, 12:55

DRUG THERAPY
smoking cessation and, 19:16-17

Duodenal ulcer
See **ULCER, PEPTIC**

DUODENOGASTRIC REFLUX
effect of smoking, 9:16

DUST
coal, obstructive airway diseases and,
7:9
cotton, byssinosis and, 7:9

cotton, "Monday morning fever" and,
7:9
cotton, obstructive airway diseases
and, 7:9-10
gold, chronic bronchitis and, 7:15
rubber, occupational hazards, 7:13

ECONOMICS

cigarette cost and cessation, 18:19
cigarette cost and consumption,
18:23-24

cigarette tax revenues, 21:18

EMPHYSEMA

(See also **BRONCHOPULMONARY DISEASES; CHRONIC OBSTRUCTIVE LUNG DISEASE**)

antitrypsin deficiency in etiology of,
6:33-34

in coal miners, 13:35

effect of smoking on mortality, 2:41

enzyme induction and, 6:28

mortality in cigar vs. cigarette vs.

pipe smokers, 3:34-35

prevalence in the United States, 6:20

small airways function and, 6:18

smoking and, 6:25

smoking and, summary of findings,
1:18-19

smoking in etiology of, 3:5

smoking in uranium miners and, 7:14

smoking levels and lung pathology,
6:24

Employee programs

See **WORKPLACE PROGRAMS**

ENVIRONMENT

effect on mortality, 2:42

ENZYME ACTIVITY

(See also **ARYL HYDROCARBON HYDROXYLASE**)

in cotinine metabolism, 14:94

effect of aromatic hydrocarbons,
12:7-9

effect of cessation of smoking, 12:41

effect of cigarette smoke condensates,
6:29

effect of cigarette smoke constituents,
12:7

effect of marijuana, 12:42-43

effect of methylcholanthrene, 12:21-
22

effect of nicotine, 12:27-28, 14:87

effect of nicotine in rat intestines,
12:76

effect of nitric oxide in rats, 14:81
effect of smoke inhalation in dogs,
14:78
effect of smoking, 1:25-26, 5:57,
12:8-9
effect of tobacco smoke, 10:16,
12:27-28, 12:75-76
in emphysema etiology, 6:28
mechanism of induction in drug me-
tabolism, 12:20-22
nicotine metabolism and, 14:87
role in carcinogenesis, 5:55, 5:57
role of RNA and protein synthesis,
12:21-22

ENZYMES

(See also **ARYL HYDROCARBON
HYDROXYLASE**)

alkaline phosphatase, 12:76
aminoazo dye N-demethylase, 12:9
guanylate cyclase, 14:80-81
role of microsomal mixed function
oxidase systems in drug metabo-
lism, 12:10-22, 12:76
role of NADPH reductase in drug
metabolism, 12:10-15
serum glutamic oxalacetic transami-
nase, 12:84

EPIDEMIOLOGY

American Cancer Society 9-State
Study, 2:15
American Cancer Society 25-State
Study, 2:12, 2:14
British Doctors Study, 2:12
California men in various occupa-
tions, 2:15
Canada Veterans Study, 2:14-15
Japanese Study, 2:14
smoking related mortality studies,
2:13
Swedish Study, 2:15
United States Veterans Study, 2:14

ERYTHROCYTES

smokers vs. nonsmokers, 12:82-83

ESOPHAGEAL NEOPLASMS

alcohol consumption and smoking in
etiology of, 5:43-44, 13:25-26
animal models, 5:44
induced by benzo(a)pyrene and etha-
nol in animals, 5:44
induced by nitrosamines in animals,
5:44
mortality in cigar vs. cigarette vs.
pipe smokers, 13:24-25

mortality ratio in cigar and pipe
smokers, 5:43
mortality ratio in smokers, 5:42-43
relative risk ratio in cigar vs. ciga-
rette vs. pipe smokers, 13:26
smoking and, summary of findings,
1:17

ESOPHAGUS

effect of smoking, 5:44
effect of smoking and alcohol con-
sumption, 13:25-26

ESTROGENS

effect on heart attack risk in males,
4:61
myocardial infarct and smoking and,
12:52

Ethanol

See **ALCOHOL**

EX-SMOKERS

absenteeism, 3:8, 3:13
activity limitation, 3:14
annual probability of dying, 2:30-34
bladder neoplasm risk, 5:46
blood chemical analysis, 12:87
blood circulation, 4:54
blood lipid levels, 12:83
blood pressure, 4:57
calcium and iodine levels in blood,
12:84
carcinoembryonic antigen levels,
12:86
chronic obstructive lung disease and
mortality, 6:10-11
coronary heart disease morbidity and
mortality rates and ratios, 4:28-
31, 4:34-35, 4:38
effect of smoking duration and
smoking levels on mortality ratio,
2:28-29
heart conditions, 3:16-17, 3:19
hospitalization, 3:14-16
laryngeal neoplasm risk, 5:34, 5:37-38
leukocyte count, 12:81
lung function, 6:23
lung function and sex ratio, 6:23
lung neoplasm mortality ratio, 5:24-
26
mortality, 2:26-30
mortality and years since quitting,
2:27-30, 2:25
mortality in cigar and pipe smokers,
13:8

- mortality ratio and reasons for quitting, 2:27-29
- myocardial infarct, 4:21
- perception of health status, 3:14-15
- personality and cessation of smoking 15-24
- physician visits, 3:15, 3:17
- respiratory tract diseases in young adults, 6:12
- small airways function, 6:14-16
- smoking levels and lung pathology, 6:24, 6:27
- EXCESS DEATHS**
(*See also* MORTALITY)
age groups in the United States, 2:11
definition, 2:11
- EXERCISE**
(*See also* PHYSICAL ACTIVITY)
effect of smoke inhalation in dogs, 14:77-78
effect of smoke inhalation in rats, 14:77
- EXTRAVERSION**
cessation of smoking and, 18:17-18
maintenance of smoking and, 18:5-7
- EYE IRRITATION**
effect of smoking in enclosed spaces, 11:26
effect of tobacco smoke, 10:21
effect of ventilation rate, 11:26-27
- FATTY ACIDS**
catecholamines and, 14:90
effect of nicotine, 14:90
effect of nicotine on levels in blood, 12:40
levels in cigarette smoke, 14:58
- FEDERAL CIGARETTE LABELLING AND ADVERTISING ACT, A:7**
- FEDERAL COMMUNICATIONS COMMISSION**
Fairness Doctrine, 18:23
- FEDERAL TRADE COMMISSION**
cigarette tar content and, 14:44
- Females**
See WOMEN
- Feminism**
See WOMEN'S MOVEMENT
- FETAL GROWTH**
(*See also* BIRTH WEIGHT)
effect of maternal exposure to carbon monoxide, 8:60
- effect of maternal smoking, 8:12, 8:17-19, 8:21
- effect of maternal smoking, summary of findings, 1:21
- effect of maternal smoking in animals, research needs, 8:78
- effect of tobacco smoke in animals, 8:52
- maternal smoking and maternal weight gain and, 8:24-25
- FETAL MORTALITY**
(*See also* MORTALITY; NEONATAL MORTALITY; PERINATAL MORTALITY)
carboxyhemoglobin levels in sheep and, 8:62
effect of maternal smoking and gestational age, 8:43
effect of maternal smoking and other factors, 8:41
research needs, 8:75
smoking, abruptio placentae, placenta previa and bleeding in pregnancy and, 8:40
- FETUS**
(*See also* PLACENTA; PREGNANCY; PRETERM DELIVERY)
effect of maternal smoking, 8:67-68
effect of oxygen availability, 8:17
- FIBER OPTICS**
in tobacco analysis, 14:9
- FIBROSIS**
smoking in asbestos workers and, 7:12
smoking levels and asbestos exposure, 7:13
- Filter cigarettes**
See CIGARETTES, FILTER
- FILTERS**
effect on carbon dioxide content, 14:38, 14:104-105
effect on catechol content in gas phase cigarette smoke, 14:106
effect on ciliotoxic agent content, 14:105, 14:107
effect on cyanide content, 14:40
effect on laryngeal neoplasm risk, 5:34-36
effect on lung neoplasm risk, 5:16, 5:18-19
effect on nitrogen oxide content, 14:39
effect on nitrosamine content, 14:39

- effect on nitrosamine content in gas phase cigarette smoke, 14:107
- effect on phenol content, 14:54, 14:57, 14:106
- effect on polonium-210 content, 14:113
- effect on smoke constituents, 14:29
- effect on tar delivery, 14:44
- effect on temperature profile, 14:35
- summary of research and development, 1:31
- FLAVORINGS**
 - in cigarette manufacturing, effect on smoke constituents, 14:28-19
- FLUORIDES, INORGANIC**
 - smoking and occupational exposure, 7:7
- FLUOROCARBON POLYMERS**
 - smoking and polymer fume fever, 7:6
- FORMALDEHYDE**
 - smoking and occupational exposure, 7:7
- 4-H Programs**
 - See* COOPERATIVE EXTENSION SERVICE
- FRAMINGHAM HEART STUDY**
 - angina pectoris, 4:46
 - high density lipoprotein levels in smokers vs. nonsmokers, 4:61-62
 - peripheral vascular disease, 4:53
 - sudden cardiac death, 4:43
- FUROSEMIDE**
 - effect of smoking on diuretic action, 12:37, 12:54
- FUTURE SMOKERS**
 - maternal, and infant birth weight, 8:26-27
 - maternal, and personality characteristics, 8:26
- GAS PHASE, CIGARETTE SMOKE**
 - chemical composition, 14:38
 - ciliatotoxic agent levels, 14:106
 - constituent levels, 15:6-7
 - constituents in main- vs. sidestream smoke, 11:6
 - definition, 14:35
 - effect of filters on ciliatotoxicity, 14:107
 - reduction of carbon monoxide, 14:104
 - reduction of catechols, 14:106
 - reduction of ciliatotoxic agents, 14:105
 - reduction of phenols, 14:106
 - reduction of nitrosamines, 14:107
 - reduction of toxicity, 14:104
 - toxic agent levels, 14:44
 - toxicity reduction methods, 14:114
- GASTRIC SECRETION**
 - effect of nicotine, 9:13-14
 - effect of nicotine in cats, 9:12-13
 - effect of smoking in peptic ulcer patients and the normal population, 9:13
- Gastric ulcer**
 - See* ULCER, PEPTIC
- GASTRITIS**
 - smoking in etiology of, 9:16
- GEORGIA HEART ASSOCIATION**
 - hypertension education program, 21:21
- GESTATION**
 - effect of maternal nicotine injection in rats, 8:54
 - smoking and duration of, 8:18
- GESTATIONAL AGE**
 - effect of maternal smoking levels on birthweight, 8:20
 - maternal smoking and birthweight, 8:19
 - maternal smoking and risk for abruptio placentae, placenta previa, and premature membrane rupture, 8:44, 8:46
 - maternal smoking and risk for preterm delivery, 8:44
- GLUTETHIMIDE**
 - pharmacokinetics in smokers vs. nonsmokers, 12:33
- GLYCERIN**
 - levels in cigarettes, 14:63
- GLYCOLS**
 - levels in cigarettes, 14:63
- GOLD**
 - dust, occupational hazards, 7:15
- GROUP PROGRAMS**
 - American Cancer Society, 19:10
 - 5-Day Plan, 19:10, 21:15-16
 - hypnosis and, 19:17-18
 - SmokEnders, 19:11, 21:16
 - Smoking Withdrawal Study Centre, 19:11

HABITUATION

opponent process model, 16:9-11,
16:14-15

HEALTH ACTIVITIES PROJECT

health education for children, 21:20

HEALTH AND NUTRITION EXAMINATION SURVEY, 3:11-12, 3:17

HEALTH EDUCATION

(*See also* **SCHOOL PROGRAMS; ADULT EDUCATION**)

evaluation of School Health Curriculum Project, 20:21

information dissemination, 23:27-28

nonschool antismoking programs for youth, 20:22-24

role of health professionals, 22:14-19

role of schools, 17:15

Saskatoon Smoking Study, 20:11-12, 23:25

summary of methodologies and programs, 1:33-34

teacher certification requirements, 23:28-31

Teenage Self Test, 20:22

HEALTH INTERVIEW SURVEY, 3:8-18

smoking prevalence data, A:13

smoking prevalence in white and black adults 1965-1976, A:15

HEALTH PROFESSIONALS

(*See also* **PHYSICIANS; NURSES; PHARMACISTS; DENTISTS**)

cessation of smoking advice, 19:13-14, 21:11-12

as health educators, 22:5-6, 22:14-19

as role models, 22:6-9

smoking habits, 22:9-14, 22:23

HEART

(*See also* **CARDIOVASCULAR SYSTEM; HEART RATE; MYOCARDIUM**)

conditions, in smokers vs. nonsmokers vs. ex-smokers, 3:16-17, 3:19

effect of nicotine, 14:78

effect of smoke inhalation and exercise in dogs, 14:78

effect of smoke inhalation in cats, 14:77

function, in animals with coronary heart disease, 4:40

Heart disease

See **CARDIOVASCULAR DISEASES; CORONARY HEART DISEASE**

HEART RATE

effect of involuntary smoking in children, 11:27

effect of nicotine, 4:58

effect of nicotine vs. cotinine, 14:91

effect of smoking, 12:15-16

fetal, effect of maternal smoking, 8:10, 8:67

sudden cardiac death and ventricular fibrillation, 4:43

sudden cardiac death and ventricular premature beats, 4:42

HEMATOCRIT

infants of smokers vs. nonsmokers, 8:69

smokers vs. nonsmokers, 12:82-83

HEMODYNAMICS

(*See also* **BLOOD CIRCULATION**)

effect of smoke inhalation in dogs, 14:76

HEMOGLOBIN LEVELS

(*See also* **CARBON MONOXIDE; CARBOXYHEMOGLOBIN LEVELS; ERYTHROCYTES**)

effect of carbon monoxide, 12:82-83

effect of cyanide, 12:83

smokers vs. nonsmokers, 12:82-83

HEREDITY

atherosclerosis in animals and, 4:9

bronchopulmonary diseases and, 1:19

coronary heart disease and, 4:66

in establishing smoking habit, 15:9-10

lung neoplasms and, 5:23

smoking and chronic obstructive lung disease risk, 6:35-36

smoking related mortality and, 2:41-42

HETEROCYCLIC COMPOUNDS

(*See also* **AROMATIC AMINES**)

in cigarette smoke, 14:52, 14:57

structural formulae of tobacco smoke carcinogens, 14:55

weakly acidic, structural formulae, 14:56

HIGH DENSITY LIPOPROTEINS

coronary heart disease and, 4:61-62

effect of oral contraceptives on levels, 4:62

- effect of smoking on levels in males vs. females, 4:61-62
- levels in smokers vs. nonsmokers, 4:61-62
- HOMOGENIZED LEAF CURING**
(See also **TOBACCO CURING**)
effect on smoking quality, 14:19
effect on tobacco leaf components, 14:27-28
- HORMONES**
antidiuretic, effect of nicotine on secretion, 12:37
corticosteroids, effect of smoking on secretion, 12:37, 12:40
effect of cessation of smoking, 15:23-24
effect of smoking, 15:20
in establishing smoking habit, 15:10
in maintenance of smoking habit, 15:20
- HOSPITAL ADMISSION RATES**
children, maternal smoking and, 11:33
smokers vs. nonsmokers vs. ex-smokers, 3:14-16
- HOSPITALS**
smoking policies, 22:20-23
- HUMECTANTS**
effect on smoke constituents, 14:29
levels in mainstream cigarette smoke, 14:63
- HYDRAZINES**
levels in cigarette smoke, 14:41
- HYDROGEN CYANIDE**
(See also **CYANIDES**)
cardiovascular diseases and, 4:62
occupational hazards, 7:7-8
pharmacology, 7:8
- HYPERGLYCEMIA**
induced by nicotine in cats, 14:90
- HYPERKINESIS**
carbon monoxide in animal model, 8:65
maternal smoking and, 8:23
- HYPEROXIA**
effect on atherosclerosis, 4:17
- HYPERTENSION**
(See also **BLOOD PRESSURE**)
biological control mechanisms, 4:56-57
cardiovascular and cerebrovascular diseases and, 4:57
myocardial infarct and, 4:20
nicotine and, 14:79
research needs, 4:58
school health education program, 21:21
smokers vs. nonsmokers, 4:57
- HYPERSENSITIVITY**
(See also **ALLERGY**)
basic mechanisms, 10:15
classification, 10:9
- HYPNOSIS**
in smoking cessation, 19:17, 19:26
- HYPOXIA**
effect of carbon monoxide in sheep fetus, 8:63-65
effect on atherosclerosis, 4:17
effect on myocardium, 4:20
fetal, effect of maternal smoking, 8:17
fetal mortality and, research needs, 8:75
fetal response in sheep, 8:64
- Illinois Antismoking Education Study**
See **UNIVERSITY OF ILLINOIS ANTISMOKING EDUCATION STUDY**
- IMIPRAMINE**
effect of smoking on pharmacokinetics, 12:33
- IMMUNE SYSTEM**
B and T lymphocytes in smokers vs. nonsmokers, 6:31
effect of cigarette smoke in rabbits, 10:18
effect of cigarette smoke on antibody response in mice, 12:59
effect of cigarette smoke on humoral immunity in mice, 10:18
effect of smoking, 10:14-20
effect of smoking on lymphocytes, 10:17
effect of smoking, summary of findings, 1:18-19, 1:23-24, 1:26
effect of smoking on cellular elements, 10:20
effect of tobacco smoke, 6:30-31, 10:5
hyperresponsiveness in smokers, 10:20
response to viral vaccines in smokers vs. nonsmokers, 12:58-59

INFANT MORTALITY

(*See also* **MORTALITY RISK; NEONATAL MORTALITY; PERINATAL MORTALITY**)

- birth weight in smoking vs. non-smoking mothers and, 8:29
- black vs. white smoking mothers, 8:28, 8:30
- British Perinatal Mortality Study, 8:29
- Collaborative Perinatal Study of the NINCDS (1959-1966), 8:30
- effect of maternal smoking, 8:10, 8:28, 8:32, 8:34-35
- effect of maternal smoking, age, parity, and education, 8:29-31, 8:33
- effect of maternal smoking and gestational age, 8:43
- effect of maternal smoking and preterm delivery, 8:42
- etiology of perinatal death in smokers vs. nonsmokers, 8:36-38
- maternal smoking levels and, 8:35, 8:39-40
- Ontario Perinatal Mortality Study, 8:33-35
- prospective and retrospective studies, 8:29
- synergism of maternal smoking and other risk factors, 8:35

INFANTS

(*See also* **SMOKING, MATERNAL**)

- breastfed, effect of maternal smoking, 8:51
- effect of maternal smoking on birth weight, 8:12-13
- effect of maternal smoking on body height, 8:19

INFECTIOUS DISEASES

(*See also* **RESPIRATORY TRACT INFECTIONS**)

- in smoking vs. nonsmoking pregnant women, 10:19

INFLUENZA

(*See also* **RESPIRATORY TRACT INFECTIONS**)

- incidence in smokers vs. nonsmokers, 10:19

INITIATION OF SMOKING

- age and, 17:7
- behavioral factors, 16:5-13

developmental and social psychology, 17:9-12

medical students, 22:18

psychoanalytic theory, 17:10-11

psychosocial factors in adolescence, 17:12-17

INTELLECTUAL DEVELOPMENT

(*See also* **LEARNING**)

effect of maternal smoking on children, 1:21, 8:21-23

INTERMITTENT CLAUDICATION

effect of carbon monoxide, 4:54

smoking and, 4:53-54

INTERNATIONAL ATHEROSCLEROSIS PROJECT

atherosclerosis risk factors, 4:8

summary of epidemiological data, 4:7

INVOLUNTARY SMOKING

absorption of nicotine by nonsmokers, 11:24

absorption of tobacco constituents by nonsmokers, 11:6

allergy and, 11:31

asthma and, 10:21

effect of psychological factors on physiologic response, 11:27

effect on angina pectoris patients, 11:30-31

effect on carboxyhemoglobin levels, 11:21, 11:23

effect on cardiac patients, 11:29-30

effect on children with respiratory diseases, 11:32

effect on fetus and breastfed infants, 8:51

effect on heart rate and blood pressure in children, 11:27

effect on lung function in asthmatic patients, 10:22

effect on nonsmokers, 10:12 11-5, 11:15, 11:28

effect on respiratory tract infections in infants, 8:45

effect on skin temperature, 11:27

health effects, 21:17

health effects, summary of findings, 1:24-25

research goals, 11:35

Inspiratory reserve volume measurements

See **RESPIRATORY FUNCTION TESTS**

IODINE

blood levels in smokers vs. nonsmokers, 12:84

ISCHEMIA

(See also **CARDIOVASCULAR DISEASES; CORONARY HEART DISEASE)**

effect of carbon monoxide and nicotine, 4:39

effect on myocardium, 4:19-20

in myocardial infarct etiology, 4:19-20, 4:39-40

sudden cardiac death and, 4:43

ISOPRENOIDS

structural formulae, 14:50

in tobacco, 14:48-49

KETONES

content in cigarette smoke, 14:42

formation from humectants, 14:63

KIDNEY NEOPLASMS, 5:47-49

mortality and risk ratios in smokers, 5:48-49

smoking and, summary of findings, 1:17

KIDNEYS

organ weight in smokers vs. nonsmokers, 12:9

KIWANIS CLUB

youth-to-youth antismoking program, 20:15

KNOW YOUR BODY PROGRAM

antismoking education component, 20:11

description, 21:20

LACTATION

(See also **BREAST FEEDING)**

effect of maternal smoking, 8:50

effect of maternal smoking, summary of findings, 1:22

effect of nicotine in animals, 8:49 and maternal smoking, research needs, 8:78-79

in smoking vs. nonsmoking mothers, 8:48

LARYNGEAL NEOPLASMS

(See also **RESPIRATORY TRACT NEOPLASMS)**

animal models, 5:34-35

aryl hydrocarbon hydroxylase inducibility and, 5:57

asbestos and smoking and, 5:34

cigar and pipe smoking and, summary of findings, 1:27

effect of alcohol consumption and smoking on risk, 5:32, 5:34

effect of cessation of smoking on risk, 5:34, 5:37-38

effect of filters on risk, 5:34-36

effect of smoking duration on risk, 5:34

effect of smoking levels on risk, 5:33-36

induced by benzo(a)pyrene in hamsters, 5:34-35

induced by cigarette smoke in hamsters, 5:34-35

morbidity and mortality in cigar vs. cigarette vs. pipe smokers, 13:24

mortality ratio in cigar vs. cigarette vs. pipe smokers, 13:24

mortality ratio in smokers, 5:32-33

radiation and smoking and, 12:90

smoking and, summary of findings, 1:16-17

LEAD

(See also **METALS)**

levels in smokers vs. nonsmokers, 12:73

smoking and occupational exposure, 7:7

LEAD-210

levels in cigarette smoke, 14:60

as tobacco contaminant, 14:20-21

LEARNING

(See also **INTELLECTUAL DEVELOPMENT)**

effect of smoking, 15:18-19

smokers vs. nonsmokers, 15:19

LEGISLATION

Federal adult education laws, 21:7

minors' purchase and use of tobacco, 23:7-8

National Consumer Health Information Act of 1976, 21:10

ordinances restricting smoking in public places, 21:18